Submit Deal

TRAVERE THERAPEUTICS (BILE ACID PRODUCT PORTFOLIO)

Summary

Travere’s bile acid product portfolio includes Cholbam® (cholic acid) and Chenodal® (chenodiol), two medications addressing rare diseases in high-need settings.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 367 M

Avg. Deal Size£ 367 M

Market Context

Sort

17 Jul 2023|United States|Biotechnology

Target: TRAVERE THERAPEUTICS (BILE ACID PRODUCT PORTFOLIO)

Bidder: MIRUM PHARMACEUTICALS

9 Service Providers

6 Bidder | 3 Vendor

32 Dealmakers

4 Bidder | 28 Vendor

£ 366 M

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy